DE60212757D1 - Verfahren zur Verwendung von Pyrrolederivaten gegen Zwangsstörungen - Google Patents

Verfahren zur Verwendung von Pyrrolederivaten gegen Zwangsstörungen

Info

Publication number
DE60212757D1
DE60212757D1 DE60212757T DE60212757T DE60212757D1 DE 60212757 D1 DE60212757 D1 DE 60212757D1 DE 60212757 T DE60212757 T DE 60212757T DE 60212757 T DE60212757 T DE 60212757T DE 60212757 D1 DE60212757 D1 DE 60212757D1
Authority
DE
Germany
Prior art keywords
compulsive disorder
pyrrole derivatives
derivatives against
compound
isoindolinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60212757T
Other languages
English (en)
Other versions
DE60212757T2 (de
Inventor
Cathryn Montgomery Clary
Sean David Donevan
Perry Steven Eisman
Richard J Kavoussi
Lyou-Fu Ma
Atul Chandra Pande
Beek Jeroen Bernard Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indevus Pharmaceuticals Inc
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60212757D1 publication Critical patent/DE60212757D1/de
Publication of DE60212757T2 publication Critical patent/DE60212757T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60212757T 2001-04-30 2002-04-16 Verfahren zur Verwendung von Pyrrolederivaten gegen Zwangsstörungen Expired - Lifetime DE60212757T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28754501P 2001-04-30 2001-04-30
US287545P 2009-12-17

Publications (2)

Publication Number Publication Date
DE60212757D1 true DE60212757D1 (de) 2006-08-10
DE60212757T2 DE60212757T2 (de) 2007-06-28

Family

ID=23103396

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60212757T Expired - Lifetime DE60212757T2 (de) 2001-04-30 2002-04-16 Verfahren zur Verwendung von Pyrrolederivaten gegen Zwangsstörungen
DE60231568T Expired - Lifetime DE60231568D1 (de) 2001-04-30 2002-04-16 Verwendung von Pyrrolederivaten gegen Angstzustände

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60231568T Expired - Lifetime DE60231568D1 (de) 2001-04-30 2002-04-16 Verwendung von Pyrrolederivaten gegen Angstzustände

Country Status (21)

Country Link
US (2) US7026332B2 (de)
EP (2) EP1254660B1 (de)
JP (1) JP2002326934A (de)
KR (1) KR20020084413A (de)
CN (1) CN1384104A (de)
AT (2) ATE424820T1 (de)
AU (1) AU783516B2 (de)
CA (1) CA2383599C (de)
CY (1) CY1109129T1 (de)
DE (2) DE60212757T2 (de)
DK (1) DK1642576T3 (de)
ES (2) ES2267943T3 (de)
HK (1) HK1094307A1 (de)
HU (1) HU228826B1 (de)
IL (2) IL149280A0 (de)
MY (1) MY129575A (de)
NZ (1) NZ518615A (de)
PL (2) PL207738B1 (de)
PT (1) PT1642576E (de)
TW (1) TWI302455B (de)
ZA (1) ZA200203347B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100955A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
BRPI0414347A (pt) * 2003-09-12 2006-11-07 Warner Lambert Co associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
WO2005105061A2 (en) * 2004-04-14 2005-11-10 Indevus Pharmaceuticals, Inc. Transdermal patch
EP1744750A2 (de) * 2004-05-06 2007-01-24 Sandoz AG Pharmazeutische zusammensetzung mit wasserabweisendem wirkstoff mit erhöhter löslichkeit
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
JP2014506603A (ja) * 2011-02-25 2014-03-17 コンサート ファーマシューティカルズ インコーポレイテッド ２−アミノ−ナフチリジン誘導体
MX2021011263A (es) * 2019-03-18 2021-10-01 Neurocycle Therapeutics Inc Uso de moduladores del receptor gabaa para el tratamiento del dolor.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607503B1 (fr) 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) * 1988-04-26 1989-11-09 Davy Mckee Ag Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (de) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimiden- und Pyrimidinylbisphosphonsäureester als entzündungshemmende Mittel
FR2678934B1 (fr) 1991-07-12 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2678932B1 (fr) 1991-07-12 1993-09-24 Rhone Poulenc Rorer Sa Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2681068B1 (fr) 1991-09-09 1993-11-19 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr) 1991-12-04 1994-01-21 Rhone Poulenc Rorer Sa Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr) 1992-09-08 1994-11-04 Rhone Poulenc Rorer Sa Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) 1994-01-12 1996-03-12 Rhone-Poulenc Rorer S.A. 2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) * 1996-03-29 1997-04-23 Lilly Co Eli Treatment of obsessive-compulsive disorder
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
AU6381000A (en) * 1999-07-29 2001-02-19 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function

Also Published As

Publication number Publication date
EP1254660B1 (de) 2006-06-28
ATE424820T1 (de) 2009-03-15
US20030022915A1 (en) 2003-01-30
PL353681A1 (en) 2002-11-04
HUP0201394A3 (en) 2003-12-29
HU228826B1 (en) 2013-05-28
ZA200203347B (en) 2003-11-26
EP1642576A3 (de) 2007-01-10
MY129575A (en) 2007-04-30
HUP0201394A2 (hu) 2002-12-28
DE60212757T2 (de) 2007-06-28
US7026332B2 (en) 2006-04-11
DK1642576T3 (da) 2009-04-14
CY1109129T1 (el) 2014-07-02
HU0201394D0 (de) 2002-06-29
NZ518615A (en) 2004-03-26
US20060128746A1 (en) 2006-06-15
EP1642576B1 (de) 2009-03-11
IL204665A (en) 2011-05-31
CA2383599A1 (en) 2002-10-30
US7553847B2 (en) 2009-06-30
IL149280A0 (en) 2002-11-10
AU783516B2 (en) 2005-11-03
PL207738B1 (pl) 2011-01-31
EP1254660A3 (de) 2003-03-26
DE60231568D1 (de) 2009-04-23
PL207725B1 (pl) 2011-01-31
JP2002326934A (ja) 2002-11-15
EP1254660A2 (de) 2002-11-06
HK1094307A1 (en) 2007-03-30
PT1642576E (pt) 2009-05-21
EP1642576A2 (de) 2006-04-05
ES2267943T3 (es) 2007-03-16
PL390683A1 (pl) 2010-05-24
CN1384104A (zh) 2002-12-11
AU2760902A (en) 2002-10-31
ATE331513T1 (de) 2006-07-15
TWI302455B (en) 2008-11-01
KR20020084413A (ko) 2002-11-07
ES2323646T3 (es) 2009-07-22
CA2383599C (en) 2006-10-31

Similar Documents

Publication Publication Date Title
ATE507224T1 (de) Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
HK1094307A1 (en) Use of pyrrole derivatives to combat anxiety
ATE469888T1 (de) Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
ATE554087T1 (de) Neue kinaseinhibitoren
ATE360417T1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
AR035763A1 (es) Compuestos derivados de diamidas heterociclicas, metodo para controlar una plaga de invertebrados y composicion que lo comprende
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
ATE455778T1 (de) Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
ATE304522T1 (de) Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten
DE60113157D1 (de) Verbessertes verfahren zur herstellung von simvastatin
DE60142304D1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
DE60218203D1 (de) Verbindungen und verfahren zur behandlung einer hyperaktiven blase
ATE497958T1 (de) Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften
ATE306485T1 (de) Verfahren zur herstellung von 2-(-5-(4- fluorphenyl)-3-pyridylmethylaminomethyl)-chroma
ATE513824T1 (de) Verfahren zur herstellung von isothiocyanato-2,2- difluorbenzo-(1,3)-dioxolen
DE602004023534D1 (de) Verfahren zur herstellung von optisch aktivem 2-alkylcystein, derivate davon und herstellungsverfahren
DE60134900D1 (de) Verfahren zur Regulierung der Behandlung von Fluiden
ATE344666T1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
ATE466095T1 (de) Stabile faltungszwischenverbindung von apolipoprotein e und verfahren zur verwendung davon
ATE319707T1 (de) Verfahren zur herstellung von chinazolinen
DE50307080D1 (de) Verfahren zur herstellung von norgalanthamin, ihren isomeren, salzen und hydraten
DE60300280D1 (de) Verfahren zur Herstellung von Azin- bzw. Oximverbindungen
UA51058A (uk) Спосіб лікування уражень суглобів

Legal Events

Date Code Title Description
8364 No opposition during term of opposition